- 2022-06-25
- Disease markers 2022
- Jing Ma
- Jiaying Luo
- Zhangkai Cheng
- Gui Chen
- Zhiman Liang
- Baoqing Sun
- Feng Wang
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Population
- Allergic rhinitis patients
- Methods
- Randomly divided into control group and study group for 7 days of treatment; control group treated with Tongqiao Biyan Pian, study group treated with Sanfeng Tongqiao Diwan
- Duration
- 7 days
- Funding
- Unclear
Objective
To explore the clinical effect of Sanfeng Tongqiao Diwan in the treatment of allergic rhinitis.Methods
Allergic rhinitis patients included in this study were randomly divided into control group and study group for 7 days of treatment. The control group was treated with Tongqiao Biyan Pian, while the study group was treated with Sanfeng Tongqiao Diwan.Results
After 7 days of treatment, the total effective rate of Sanfeng Tongqiao Diwan was 75.76%, which was higher than that of Tongqiao Biyan Pian (65.62%). The scores of visual analogue scale (VAS), symptom relief, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and Epworth sleepiness scale (ESS) in both groups were significantly improved before and after treatment (P < 0.05), and the improvement was most significant 24 hours after treatment. The adverse reactions in both groups were low.Conclusion
Sanfeng Tongqiao Diwan can significantly alleviate the symptoms and improve the quality of life of patients with allergic rhinitis, with less adverse reactions.